Markets
BSE See NSE See 26,740.28
46.00 (0.17%)
collapse Related Readings collapse

Aurobindo Pharma Gets USFDA Approval For Generic Diovan HCT

By Shrikant Akolkar | 3/22/2013 3:42 PM Friday

Aurobindo Pharma has reported receiving final approval for the Valsartan and Hydrochlorothiazide tablets (brand name Diovan HCT held by Novartis). The drug is indicated in the treatment of hypertension to lower blood pressure. The market size of this drug is USD 1.7 billion (Rs 9350 crore) as per the company’s BSE filings. Aurobindo has said that the product is ready for launch and that this will happen soon.

Drug major Mylan has already launched an authorised generic version of this drug in USA. We believe that Aurobindo is the first to launch the generic of this drug considering that Mylan’s was an authorised generic.

We spoke to the company spokesperson, who declined to comment on the pricing and market share of the drug. However, he did say that the company expects to see about 3-4 generic players in the market. Considering this, about 20% market share looks achievable for Aurobindo. Since it is the first to launch, there would not be a massive erosion of price initially. However, as the drug has already fallen out of patent cover, new players would try to enter the market as faster as possible. Once other companies start launching their versions of the drug, the price will go down.

Considering 80% price erosion and 10% market share for Aurobindo, it can be estimated that the company may achieve revenues of about Rs 700 crore from the drug. Of course, these numbers are based on the assumption that the company makes the best of this opportunity.

With this approval, Aurobindo Pharma has a total of 181 ANDA approvals from USFDA, of which 156 are final and 25 are tentative approvals.

Find More Articles on: Markets, DSIJ Mindshare, Product, Large Cap

DSIJ
Mindshare

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.15 p.m. on December 9.

Beneficiaries of the cashless mantra trade higher on bourses

Beneficiaries of the cashless mantra trade higher on bourses

There are a host of stocks which are likely to benefit from the governments' big Digital push. These stocks have already seen a big run-up, post demonetisation. However, more upside is left in the stocks.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 9 opened up. BSE Sensex is trading at 26779.11, up by 84.83 points and the Nifty is trading at 8266.65, up by 19.80 points. Meanwhile, following stocks are close to their 52 week high as on December 9.

Banco Products runs low after rollback of buyback

Banco Products runs low after rollback of buyback

Banco Products’ board of directors have decided to drop the proposal of buyback of equity shares of the company and decided not to further proceed with the proposal.

Quarterly Result: Jindal Steel & Power Ltd

Quarterly Result: Jindal Steel & Power Ltd

Jindal Steel & Power Ltd., is currently trading at Rs. 73.95, up by 0.85 points or 1.16% from its earlier closing of Rs. 73.1 on the BSE. The company's net loss for the quarter stands at Rs 745.98 cr against Rs 909.53 cr.

Markets @ 11 am: Movers and Shockers

Markets @ 11 am: Movers and Shockers

Following are the top gainers and losers as of December 9. Intellect Design is the largest gainer; whereas MMTC is the largest loser. 

IL&FS Engineering & Construction Company shines on bagging REC order

IL&FS Engineering & Construction Company shines on bagging REC order

IL&FS Engineering & Construction Company (IL&FS ECC) has emerged as the lowest bidder for Rural Electrification Corporation (REC) works worth Rs 225 crore crore in Jharkhand. 

Sheela Foams IPO lists at a premium of 39%

Sheela Foams IPO lists at a premium of 39%

Maker of India’s most loved mattresses brand ‘Sleepwell’ has listed with a massive premium of close to 39 per cent on the bourses. The Rs 510-crore initial public offer was oversubscribed 5.09 times on December 1, the last day for subscription. The issue was opened on November 29.

Tanla Solutions hits new 52-week high

Tanla Solutions hits new 52-week high

Tanla Solutions has hit new 52-week high on December 9. The scrips are witnessing high volume with thirty day SMA of 40.85. The shares of the company which previously closed at Rs 49.95; opened at Rs 51.50 and as at 9.52 am are trading at Rs 57.35, up by 14.81 per cent.

Stock in focus: KPR Mill

Stock in focus: KPR Mill

KPR Mill, which had earlier proposed a buy-back has finally got approval from its board. The scrip of KPR Mill by default is expected to spice up. 

Market
CHIT CHAT

What is your view on markets today?

200  Characters Remaining.
Please LOGIN  to post your comments or Click here to go back.
Shubham Maheshwari Dec 09 12:58PM
Buy ugar sugar work for short term profit
MANISH TYAGI Dec 09 12:54PM
@rajiv Nice timing, swing on tara
VINAY HEGDE Dec 09 12:49PM
PASSWORD iA9u1LVE
rajiv jha Dec 09 12:44PM
Elnet tech for short term
rajiv jha Dec 09 12:43PM
Pincon spirit also good for long term

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »